Patents by Inventor Yu Jau Chen
Yu Jau Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20230085803Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: ApplicationFiled: November 22, 2022Publication date: March 23, 2023Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
-
Patent number: 11536713Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: GrantFiled: December 24, 2010Date of Patent: December 27, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
-
Patent number: 11124773Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: GrantFiled: October 6, 2011Date of Patent: September 21, 2021Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20200385686Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: August 14, 2020Publication date: December 10, 2020Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20130288248Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: October 6, 2011Publication date: October 31, 2013Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20130019327Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: ApplicationFiled: December 24, 2010Publication date: January 17, 2013Inventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
-
Patent number: 8343761Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: GrantFiled: July 21, 2011Date of Patent: January 1, 2013Assignees: Chugai Seiyaku Kabushiki Kaisha, Pharmalogicals Research Pte. Ltd., CIEA International Inc.Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
-
Publication number: 20120015402Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: ApplicationFiled: July 21, 2011Publication date: January 19, 2012Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, CIEA INTERNATIONAL INC., PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
-
Patent number: 8008076Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: GrantFiled: April 27, 2005Date of Patent: August 30, 2011Assignees: Chugai Seiyaku Kabushiki Kaisha, Pharmalogicals Research Pte. Ltd., CIEA International Inc.Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim
-
Publication number: 20080187537Abstract: An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.Type: ApplicationFiled: April 27, 2005Publication date: August 7, 2008Inventors: Masayuki Tsuchiya, Masami Suzuki, Kenji Yoshida, Etsuko Fujii, Miho Watanabe, Koichi Matsubara, Yu Jau Chen, Juliana Sim